Pharmaceutical companies and medical device manufacturers are evolving to become integral parts of the healthcare value chain. This means that increased connectivity and communication are expected by all stakeholders from payers to providers to patients.
Precision medicine, digital health products, and lifestyle tools that incorporate machine learning and artificial intelligence now represent a greater percentage of life science companies portfolios than they did even a few years ago. And while these connectivity trends promise to improve both the patient experience and clinical outcomes, they also increase the potential attached surface for cyber-criminals, requiring a much more robust approach to cybersecurity and privacy.
In this paper, our Life Sciences team examines four primary signals of change and four strategic imperatives that represent the future of life sciences.
